For Healthcare Professionals

For Healthcare Professionals

Just test for APDS

Learn about a sponsored,
no-charge genetic test for APDS.

Activated PI3K Delta Syndrome (APDS) is a rare, genetic primary immunodeficiency 1-4

If you suspect your patient has APDS, it’s time to test.

Pharming Healthcare, Inc. has partnered with Invitae to offer genetic testing and counseling for individuals who are suspected to have APDS. APDS is a rare primary immunodeficiency, which affects approximately 1-2 people per million, and occurs when there is an autosomal dominant variant in either of two genes, PIK3CD or PIK3R1, which make parts of the PI3K delta protein that helps control the development and function of T and B cells. 1-4

Since APDS was only recently fully characterized and shares many features of other immune disorders, patients with APDS may have been previously misdiagnosed with other conditions. 5 Immunologists may mistake APDS for common variable immune deficiency (CVID) or hyper IgM syndrome (HIGM), while hematologists may not realize their patient with refractory cytopenias or auto immune lymphoproliferative syndrome (ALPS) actually has APDS. 5-7

Your content goes here. Edit or remove this text inline or in the module Content settings. You can also style every aspect of this content in the module Design settings and even apply custom CSS to this text in the module Advanced settings.

Signs and symptoms of APDS start in childhood, and patients are vulnerable to repeat infections and immune dysregulation such as lymphadenopathy, splenomegaly, autoimmune cytopenias, and even lymphoma. 9

Patients are often misdiagnosed with other immunodeficiencies or autoimmune disorders and have a protracted course to obtain a correct diagnosis. 5

Genetic testing is the only way to definitively diagnose APDS and other primary
immunodeficiencies, which may have targeted treatment options and help identify patients for participation in clinical research. 6-8

“Early, accurate diagnosis can change
a person’s life and help get timely
appropriate treatments.”

Dr. Nicholas Hartog
Immunologist

“Early, accurate diagnosis can change
a person’s life and help get timely
appropriate treatments.”

Dr. Nicholas Hartog
Immunologist

A goal of early diagnosis and treatment is to interrupt the disease evolution 5,9,10

The navigateAPDS sponsored testing program is designed to eliminate barriers to genetic testing and increases certainty in obtaining a correct diagnosis by enabling patients suspected of having APDS, and their family members, to have access to genetic testing and counseling.

NavigateAPDS Program Eligibility

This sponsored, no-charge program is available to individuals in the U.S. and Canada who meet any two of the bulleted criteria below:

Clinical Features

  • Onset of symptoms under 12 years of age
  • Documented severe recurrent sinopulmonary infections (> 2
    events within 3 years of each other)
  • Bronchiectasis
  • Lymphadenopathy for greater than one month
  • Any nodular lymphoid hyperplasia
  • Chronic hepatomegaly or chronic splenomegaly
  • Severe, persistent, or recurrent Herpesviridae infections (eg, EBV, cytomegalovirus)
  • Autoimmune cytopenia
  • Enteropathy
  • Lymphoma

 

Laboratory

  • Hypogammaglobulinemia
  • Elevated levels of immunoglobulin M
  • Reduced number of CD3+CD4+ T cells; increased number of
    follicular helper T cells
  • Reduced number of naïve T cells

History

  • Primary Immune Deficiency diagnosis
  • Common Variable Immune Deficiency (CVID) phenotype or
    direct family member with CVID phenotype
  • Relative with PIK3CD or PIK3R1 genotype (first or second
    degree)

 

APDS may be present in multiple members of a family, so family members of patients with APDS
should undergo genetic testing.8

Blood Kit
+ EDTA (purple-top) blood tube

Buccal Swab Kit
+ Two (2) – ORAcollect Dx
(OCD-100) Buccal Swabs

Saliva Kit
+ Saliva (OG-500/510)
collection tube

Stay informed

Sign up for APDS updates

Genetic Counseling Is Available Both Before and After Testing

Individuals tested through the navigateAPDS program are eligible for both pre-test and post-test genetic counseling to help them understand their test results. This service is provided through GeneMatters, an independent genetic counseling service, and is made available by Pharming at no charge.

If requested, patients will be contacted by GeneMatters to schedule an appointment.
Learn more about this service at gene-matters.com.

It’s never too late to access genetic counseling support.

Step 1A:

Z

Physicians can ‘check’ the box on the  Invitae Test Requisition Form on the bottom of page 1, authorizing Invitae to share the necessary information with GeneMatters to complete the post-test genetic counseling.

Or – Step 1B:

Complete and fax the separate referral form below, requesting pre- and/or post-test genetic counseling. Fax the form with the signed patient consent to 612-808-5186.

Step 2: Patients will be contacted by GeneMatters via text or email to schedule an appointment, generally within 24-48 hours of receipt of the faxed referral form. Patients will receive appointment reminders once scheduled.

Step 3: Genetic counseling occurs with the patient/family, at a time that is convenient with their schedule.

Step 4: Following the session, the counselor from GeneMatters will send a report to relevant physician (if approved by patient) via fax and to the patient via email.

Benefits of Genetic Counseling

During a 30-to 60-minute phone or video consultation, a GeneMatters genetic counselor can help patients:

  • Understand genetic test results
  • Make informed healthcare decisions
  • Understand any additional risk based on family history
  • Decide if additional testing is right for them

Get to know AllaboutAPDS.com

References:
1. Activated PI3K-delta syndrome. Orphanet. Accessed April 26, 2021. https://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=EN&Expert=397596
2. Lucas CL, et al. Nat Immunol. 2014;15:88-97.
3. Angulo I, et al. Science. 2013;342(6160):866-871.
4. Lucas CL, et al. J Exp Med. 2014;211(13):2537-2547.
5. Jamee M, et al. Clin Rev Allergy Immunol. 2019;May 21.
6. Rotz, SJ, et al. Pediatr Blood Cancer. 2018; 65:e27260.
7. Kulm E, et al. Oral abstract presented at the 62nd Annual ASH Meeting; Dec 5-8, 2020
8. Chinn IK, et al. J Allergy Clin Immunol. 2020;145(1):46-69.
9. Maccari ME et al. Front. Immunol. 2018;9: Article 543.
10. Elkaim E et al. J Allergy Clin Immunol. 2016;138(1):210-218.

While third parties and commercial organizations may provide financial support for this program, tests and services are performed by Invitae. Healthcare professionals must confirm that patients meet certain criteria to use the program. Third parties and commercial organizations may receive de-identified patient data from this program, but at no time would they receive patient identifiable information. Third parties and commercial organizations may receive contact information for healthcare professionals who use this program. Genetic testing and counseling are available in the US and Canada only. Healthcare professionals and patients who participate in this program have no obligation to recommend, purchase, order, prescribe, promote, administer, use or support any other products or services from Invitae or from third parties or commercial organizations.